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Combined therapyMost cancer cells exhibit an accelerated glycolysis rate compared to normal cells. This metabolic change is
associated with the over-expression of all the pathway enzymes and transporters (as induced by HIF-1α and
other oncogenes), and with the expression of hexokinase (HK) and phosphofructokinase type 1 (PFK-1)
isoenzymes with different regulatory properties. Hence, a control distribution of tumor glycolysis, modiﬁed
from that observed in normal cells, can be expected. To deﬁne the control distribution and to understand the
underlying control mechanisms, kinetic models of glycolysis of rodent AS-30D hepatoma and human cervix
HeLa cells were constructed with experimental data obtained here for each pathway step (enzyme kinetics;
steady-state pathway metabolite concentrations and ﬂuxes). The models predicted with high accuracy the
ﬂuxes and metabolite concentrations found in living cancer cells under physiological O2 and glucose
concentrations as well as under hypoxic and hypoglycemic conditions prevailing during tumor progression.
The results indicated that HK≥HPINGLUT in AS-30Dwhereas glycogen degradation≥GLUTNHK in HeLa were
the main ﬂux- and ATP concentration-control steps. Modeling also revealed that, in order to diminish the
glycolytic ﬂux or the ATP concentration by 50%, it was required to decrease GLUT orHK orHPI by 76% (AS-30D),
and GLUT or glycogen degradation by 87–99% (HeLa), or decreasing simultaneously the mentioned steps by
47%. Thus, these proteins are proposed to be the foremost therapeutic targets because their simultaneous
inhibition will have greater antagonistic effects on tumor energy metabolism than inhibition of all other
glycolytic, non-controlling, enzymes. This article is part of a Special Issue entitled Bioenergetics of Cancer.O, fructose 1,6 bisphosphate
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Cancer treatments are mostly based on the higher susceptibility of
tumor cells todamage causedby radiation and chemotherapy comparedto normal non-proliferating cells. However, their severe side effects in
the patients and the frequent lack of tumor response (due to inherent or
acquired resistance) make necessary the development of novel
therapeutic strategies to ﬁght this deadly disease. Hence, the identiﬁ-
cation of the main differences at the molecular and functional levels
between normal and tumor cells is essential in the search for new
therapeutic targets.
In this regard, the most frequent metabolic alteration in the
majority of tumor cells is a higher glucose consumption (with a
concomitant higher lactate production) compared to normal cells
[reviewed in 1,2]. The accelerated glycolysis rate can provide the
required glycolytic intermediary precursors for DNA, protein and lipid
synthesis necessary to sustaining the active proliferation of tumor
cells. Moreover, glycolysis can be the main energy-generating
pathway under conditions where mitochondrial function is absent
or diminished such as in the initial non-vascular stages of tumor
progression where hypoxic conditions prevail.
The cellular mechanisms involved in augmenting the glycolytic ﬂux
are the simultaneous increased transcription of the genes encoding
glycolytic enzymes and transporters in processes mediated by the
hypoxia-inducible factor 1α (HIF1α) and other oncogenes [reviewed in
3–5]. The higher transcription coupled to higher translation are
responsible for the increased contents and activities of glycolytic
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HIF-1α induces the expression of speciﬁc glycolytic protein isoforms (i.e.,
GLUT1, GLUT3, HKI and II, PFK-L, ALDO-A and C, PGK1, ENOalpha- PYK-
M2, LDH-A and PFKFB-3)which are not usually found together in normal
cells. Some of these isoforms show lower sensitivity to physiological
inhibitors and lower afﬁnity for products, thus favoring a higher forward
(glycolytic) rate compared to normal cells [reviewed in 5].
Because of its relevance on tumor metabolism, inhibition of
glycolytic ﬂux has been considered an alternative strategy for cancer
treatment [reviewed in 6]. However, since both tumor and non-tumor
cells contain a similar set of glycolytic enzymes, it is mandatory to ﬁnd
striking differences in pathway control so that the tumor enzyme(s)
with the highest control be different to those in normal cells. Perhaps
some of the side-effects induced by anticancer glycolytic drugs have
derived from their lack of speciﬁcity, targeting both cancer and non-
cancer cells.
Metabolic Control Analysis (MCA) has shown that the control of a
pathway ﬂux or a metabolite concentration is distributed in different
degrees among all the pathway enzymes, thus circumventing the
misleading and qualitative concept of the “rate-limiting step” and
moving into a quantitative analysis of the control of metabolic
pathways [7–9]. MCA allows for the quantitative determination of the
degree of control that each enzyme has over the pathway ﬂux and the
intermediary concentrations, namely, the ﬂux control coefﬁcient (C
J
Ei)
and the concentration control coefﬁcient (CMEi), respectively, where J is
ﬂux, M is a metabolite concentration and Ei is a pathway enzyme. A
practical deﬁnition of these coefﬁcients is the percentage of change in
ﬂux or metabolite concentration when a 1% change in a pathway
enzyme activity is attained.
By applying different experimental approaches such as elasticity
analysis and metabolic modeling, the control distribution of a
metabolic pathway can be determined [7,8]. The advantages of the
elasticity analysis strategy are that it allows determining of the control
distribution in living cells, and that it is not required to know the
complete set of the kinetic parameters of the pathway enzymes. In a
previous work, elasticity analysis was applied to glycolysis in rodent
AS-30D hepatoma [10]. The results indicated that the pathway was
mainly controlled by the glucose transporter (GLUT) plus hexokinase
(HK) segment (71%; i.e., C
J
GLUT+HK=0.71), with lesser control
attained by phosphofructokinase 1 (PFK-1) (C
J
PFK-1=0.06). The rest
of the control (C
J
Ei=0.25) resided within the aldolase (ALDO) to
lactate dehydrogenase (LDH) segment [10].
As elasticity analysis relies on quantiﬁable small changes in
pathway intermediary concentrations, thus dividing the analyzed
pathway in segments, this approach determines control coefﬁcients
only by group of enzymes. Hence, in our previous study it was not
possible to deﬁne in the glucose-6-phosphate producing segment
which individual step, GLUT, HK or even glycogen degradation, was
exerting the main ﬂux control.
Kinetic modeling of a metabolic pathway integrates all available
information (detailed kinetic properties of the individual enzymes and
transporters, metabolite concentrations and pathway ﬂuxes) into a
functional, cross-talking network that attempts to simulatewhat occurs
in the intracellular milieu [reviewed in 8,11]. Thus, the aim of kinetic
modeling is to construct a model able to predict the ﬂuxes and
concentrations found in a cell under different speciﬁcmetabolic steady-
states. Validated models allow for the identiﬁcation of the mechanisms
by which a metabolic pathway is controlled and also provide the
individual C
J
Ei and CMEi for each pathway step. By extending this approach
to normal (host, normal cells) and pathologic systems (tumor cells,
parasites) the enzymes and transporters with the highest control in the
latter and low control in the former can be identiﬁed and hence
proposed as the best and most adequate therapeutic targets [8,12].
In the present work, we report on the kinetic modeling of
glycolysis in rat AS-30D hepatoma and in human HeLa tumor cells
under normoxic and physiological glucose concentration conditionscharacteristics of in vitro culture experimentation and under hypoxic
and glucose deprivation conditions prevailing during tumor forma-
tion. The results indicated that in the evaluated conditions, the ﬂux
control was sharedmainly amongHK≥HPINGLUT in AS-30D cells and
glycogen degradation≥GLUTNHK in HeLa cells. Further modeling
analysis showed that simultaneous inhibition of these controlling
steps has greater negative effects on tumor glycolysis than inhibition
of non-controlling reactions.
2. Experimental procedures
2.1. Enzymes and chemicals
HK, G6PDH, HPI, ALDO, GAPDH, αGPDH, αGPDH/TPI, PYK/LDH,
LDH, G1P, G6P and F6P were purchased from Roche (Manheim,
Germany). Recombinant enzymes ENO, PPi-PFK and PGK from
Entamoeba histolytica were those previously described [13]. Glucose
(Glu), 6PG, FBP, G3P, 2PG, 3PG, PEP, Pyr, Rib5P, Ery4P, Xy5P, ATP, ADP,
GTP, DTT, cysteine, NADH, NAD+, NADP+, 6PGDH, amyloglucosidase,
TK, TA, MgCl2 and lyophilized ALDO,αGPDH and TPI were from Sigma
(St Louis, MO, USA). DHAPwas from Fluka (Buchs, Switzerland). Mops
and Hepes were from Research Organics (Cleveland, Ohio, USA).
Potato PPi-PFK was puriﬁed as previously described [14].
2.2. Enzyme activities
Clariﬁed cytosolic extracts fromAS-30DandHeLa cellswereprepared
as previously described [10]. Glycolytic enzyme activities and afﬁnity
constants were determined for the forward (glycolytic) and reverse
(gluconeogenic) reactions in 50 mMMops buffer pH7.0 (assay buffer) at
37 °C by following the NAD(P)+ reduction or NAD(P)H oxidation at
340 nm in a spectrophotometer (Agilent; Santa Clara, CA, USA). Standard
kinetic assays were initially used [15,16], but the substrate concentra-
tions were always adjusted to ensure theywere saturating for the tumor
cell enzymes. The activities were determined under initial-rate condi-
tions; the reactionswere started by adding the speciﬁc substrates and the
absorbance baseline in the absence of one substrate was always
subtracted. PGM, AlaTA and 3PGDH activities were determined by
standard assays [15,16]. TK and TA were measured according to [17].
The Ery4P, FBP and 6PG inhibition on HPI in the forward direction
was determined in assay buffer containing 5 mM MgCl2, 1 mM PPi,
0.15 mM NADH, 1 U E. histolytica PPi-PFK, 0.36 U ALDO, 9 U TPI, 3.1 U
αGPDHand 0.003–0.014 mg of cytosolic extract plus 13.8–28 μMEry4P,
30–60 μM6PGor 3–10 mMFBP. The reactionwas started by addingG6P
(0.1–7 mM). HPI inhibitionwas also evaluated in the reverse reaction in
assay buffer containing 1 mMNADP+, 2 UG6PDH, and 13–55 μMEry4P,
40–90 μM 6PG or 3–10mM FBP, and 0.001–0.01 mg of extract. The
reaction was started with the addition of 0.05–10 mM F6P.
PFK-1 activity was determined according to [10] with lyophilized
(ammonium-free) coupling enzymes.
2.3. Steady-state metabolite concentrations
AS-30D hepatoma cells were collected from rat ascites ﬂuid. HeLa
cells were cultured under normoxic (95% air–5% CO2) conditions in
Dulbecco-MEM medium at 37 °C as previously described [18]. For
hypoxic conditions, HeLa cells were initially grown under normoxia;
then at 75–90% conﬂuency, cells were subjected for 24 h to 0.1–0.2%
oxygen in ahumidiﬁedhypoxia incubator chamber (Billups-Rothenberg,
California, USA) as described before [19].
The experimental protocol to attain glycolytic ﬂux under steady-
state conditions was described elsewhere [10]. Brieﬂy, the cells were
harvested, washed and re-suspended in Krebs–Ringer medium
(125mM NaCl, 5 mM KCl, 1 mM MgCl2, 1.4 mM CaCl2, 1 mM KH2PO4,
and 25 mM Hepes, pH 7.4). The cells were incubated at 37 °C under
orbital shaking; after 10 min, 5 mMglucose (or 1 mM for AS-30D under
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and the reaction was terminated by perchloric acid (3% v/v, ﬁnal
concentration) extraction.
Glycolytic metabolite concentrations were determined as previ-
ously described [10]. The concentrations of NAD+, G1P, alanine and
6PG were determined in neutralized extracts as described before by
using LDH; PGM plus G6PDH; AlaTA plus LDH and 6PGDH,
respectively [20]. The Ery4P concentration was determined in
50 mM Hepes, 1 mM EGTA, pH 7.4, plus 0.7 mM Xy5P, 5 mM MgCl2,
0.5 mM NADP+, 0.04 mM thiamine pyrophosphate (TPP), 1 U/ml of
each HPI and G6PDH, and 0.5 U/ml of TK.
For F2,6BP determination, after the 3 min incubation with glucose,
the cells were quickly spun down; the pellet was re-suspended in
25 mM Tris–HCl pH 7.6 and the cells were disrupted by freezing in
liquid N2 and thawing at 37 °C three times. The homogenate was
centrifuged at 20,800×g for 3 min at 4 °C. The supernatant was
alkalinized with NaOH to a ﬁnal concentration of 0.1 mM and heated
at 80 °C for 5 min. The sample was centrifuged and the supernatant
was neutralized with acetic acid. F2,6BP was determined by using
potato PPi-PFK as described elsewhere [14].
For determination of the total intracellular Pi, cells were incubated
for 3 min with glucose, and then a sample of 1 ml was withdrawn and
centrifuged at 800×g for 30 s. The cell pellet was washed three times
with saline (0.9% NaCl) and re-suspended in 1 ml of the same solution.
The cellular suspension was divided into two; the ﬁrst sample was
centrifuged at 20,800×g for 1 min and the supernatant was recovered
whereas the second sample was extracted with perchloric acid (3% v/v
ﬁnal volume), centrifuged for 5 min as above and the supernatant
was recovered. Pi was determined in the supernatants as described
elsewhere [21]. The intracellular total Pi content was calculated from
the difference between the Pi present in the ﬁrst supernatant
(extracellular Pi) from that in the second supernatant (extracellular
plus intracellular Pi). The concentration of cytosolic free Pi was
calculated assuming that only 53% of the total content was in its free
form, as previously determined in hepatocytes [22].
2.4. Metabolic ﬂuxes
For the determination of the glycogen synthesis and degradation
ﬂuxes, AS-30D cells (15 mg protein/ml)were pre-incubated at 37 °C for
10 min in Krebs–Ringer medium. Then, an aliquot was withdrawn
(t=0) and 5 mMglucosewas added to the cellular suspension and kept
under the same conditions. Aliquots were taken at 10 and 30 min,
immediately centrifuged, and the cellular pellet was frozen in liquid N2
and kept at −70 °C until use. The pellet was further re-suspended in
0.3 ml of 30% KOH and heated for 30 min at 90 °C; afterwards, the
sample was mixed with 0.1 ml 6% Na2SO4 and 0.9 ml 100% ethanol and
centrifuged at 20,800 g for 5 min. The pelletwaswashed oncewith 1 ml
of 80% ethanol and let dry at room temperature. Then, the pellet was re-
suspended in 0.5 ml 0.2 M acetate buffer pH 4.8 plus 5 U amylogluco-
sidase and incubated for 1 h at 37 °C. Glucose units derived from
glycogen breakdown were determined by enzymatic analysis by using
HK and G6PDH [20] and reported as nmol of glucose equivalents. After
the addition of glucose, the glycogen degradation rate was calculated
from the difference of glucose equivalents in glycogen from the 10 min
minus 0 min incubation, whereas the glycogen synthesis rate was
calculated from the difference of glucose equivalents in glycogen from
the 30 minminus 10 min incubation. For HeLa cells, glycogen synthesis
and degradation rates were determined in cells (5–7 mg protein)
incubated with and without glucose, respectively. The samples were
taken at 0 and 3 min and treated as described above.
For the pentose phosphate pathway (PPP) ﬂux, AS-30D cells were
incubated as described above for glycogen metabolism analysis. After
glucose addition, samples were withdrawn at 2, 4 and 6 min and
immediately precipitated with perchloric acid, centrifuged and the
supernatant neutralized. The 6PG content was determined in theneutralized extracts by using a 6PGDH assay [20]. The rate was
calculated from the differences in 6PG concentrations at different time
points.
The pyruvate consumption rate by mitochondria (mitochondrial
pyruvate metabolism; MPM) was estimated from the total cellular
oxygen consumption rate minus that in the presence of 5 μM
oligomycin, and assuming that the main substrate consumed by
mitochondria was the endogenous pool of pyruvate generated by the
cells (equivalent to 4 mg cellular protein) incubated with 5 mM
glucose for 5 min. For the calculations it was assumed that 6 mol of O2
(12 atoms oxygen) are consumed per mol of completely oxidized
glucose. It is noted that the MPM ﬂux is the result of the coordinated
activities of the pyruvate transporter, pyruvate dehydrogenase
complex, Krebs cycle enzymes, respiratory chain complexes, adenine
nucleotide translocator, Pi carrier and ATP synthase.
For the majority of the parameters described above (enzyme
activities, metabolite concentrations and ﬂuxes) at least two different
batches of cells were assayed. The high dispersion in the experimental
data is very common when using non-chemostat cultures and when
using different batches of cellular cultures. On the other hand, lower
dispersions can be certainly obtained by measuring triplicates of one
homogeneous cell culture, but such results only represent one
independent sampling.
2.5. Construction of the kinetic models
The models were constructed by using the software Gepasi v 3.3
[23] available at the web site http://www.gepasi.org/. Fig. 1 dia-
grammed the pathway reactions considered in both models. The
reactions were written in the program as described in Table S1 and a
summary of all the used kinetic parameters is provided in Tables S2,
S3, and S4 of supplementary material.
All glycolytic reactions (including those of HK, PFK-1 and PYK)were
considered reversible. For most of them, their Vm values were
determined in cytosolic extracts in the forward and reverse reactions
(Table 1) thus avoiding the use ofKeq values taken from the literature in
the rate equations (see below). Since these Vm values actually
corresponded to those of the enriched cytosolic fractions, these were
also experimentally determined in whole cells which were solubilized
with 0.02% Triton X-100 to obtain the corresponding Vm in total cellular
protein units (Table S3); the latter Vm values were used in the models.
The kinetic parameters Vmf, Vmr and Km for substrates, products
and modulators were all determined under the same conditions of pH
(7.0) and temperature (37 °C) (Table 1), whereas those of the glucose
transporters were previously determined by our research group [24].
The oxidative and non-oxidative PPP sections, the glycogen
synthesis and degradation pathways and the MPM branches were
simpliﬁed and considered as non-reversible reactionswith the constant
ﬂux values shown in Table 2. The glycogen metabolism reactions only
included the initial substrates and the ﬁnal products without consid-
ering the intermediate reactions catalyzed by PGM. The oxidative PPP
section did not include the NADPH production whereas the non-
oxidative section only included the reaction catalyzed by TK.
The cellular ATP consuming processes (ATPases) were represented
as amass-action irreversible reactionwith an adjusted k value of 0.0042.
To maintain the pyridine and adenine nucleotide balances, the DHases
and adenylate kinase (AK) reactionswere used, respectively,withmass-
action reversible kinetics whose values were adjusted at k1=250 and
k2=1 and k1=1 and k2=2.26, respectively. Conserved moieties were
[ATP]+[ADP]+[AMP]=11.3 mM and [NADH]+[NAD+]=1.35 mM.
In the pathway modeling, metabolite concentrations were initial-
ized at the values found in the cells (Tables 3 and 4). Fixed metabolite
concentrations were used for lactate, glycogen, 6PG, Ery4P, F2,6BP, Pi,
citrate and Xy5P at the values shown in Tables 2–4 (summarized in
Table S4 of supplementary material) except for Pi, for which only 53%
of the total Pi content was assumed to be free Pi [22].
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Fig. 1. Pathway reactions included in the kinetic models of glycolysis in AS-30D and HeLa tumor cells. Solid arrows indicate whether reactions are considered non-reversible or reversible in
Gepasi; dotted arrows indicate allostericmodulators; dashed arrows indicate PPP existing reactions not included in themodel. DHases; NADHconsuming enzymes; ATPases, ATP-consuming
processes; PPP, pentosephosphatepathway;MPM,mitochondrial pyruvatemetabolism.ATP stoichiometrywas calculatedbyusingP/O ratios of 2.5 and1.5 forNADHandFADH2, respectively.
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The rate-equations used for each reaction are described below.
The kinetics of GLUTwas introduced as amonosubstrate reversible
Michaelis–Menten equation (Haldane's equation) [25]:
v =
Vmf Gluout½ −
Gluin½ 
Keq
 
KGluout 1 +
Gluin½ 
KGluin
 
+ Gluout
in which Gluout and Gluin and KGluout and KGluin are the extra- and
intra-cellular glucose concentrations and the enzyme's afﬁnity
constants (Km values), respectively; Keq is the equilibrium constant;
and Vmf is the maximal velocity in the forward reaction.The HK rate equation was described as random bi-substrate
Michaelis–Menten [25]:
v =
Vmf
KaKb
A½  B½ − P½  Q½ 
Keq
 
1 +
A½ 
Ka
+
B½ 
Kb
+
A½  B½ 
KaKb
+
P½ 
Kp
+
Q½ 
Kq
+
P½  Q½ 
KpKq
+
A½  Q½ 
KaKq
+
P½  B½ 
KpKb
in which [A] and [B] represent the substrate concentrations (Glu and
ATP, respectively), whereas [P] and [Q] represent the product
concentrations (G6P and ADP, respectively). Ka, Kb, Kp and Kq
represent the enzymes Km values for their respective ligands.
The HPI rate equationwas introduced as amonoreactant reversible
equation with competitive inhibition by Ery4P, 6PG and FBP:
v =
Vmf
G6P½ 
KG6P
−Vmr F6P½ 
KF6P
1 +
G6P½ 
KG6P
+
F6P½ 
KF6P
+
ERY4P½ 
KERY4P
+
6PG½ 
K6PG
+
FBP½ 
KFBP
Table 1
Kinetic parameters of AS-30D and HeLa glycolytic enzymes and transporter.
Enzyme AS-30D HeLa Enzyme AS-30D HeLa
GLUT Vmf 0.055a,e 0.017a,e GAPDH Vmf 1b 2b
Km Glu 0.52a 9.3a Vmr 0.9b 2.5b
HK Vmf 0.46b 0.06a KmG3P 0.29 0.19
Km Glu 0.18b 0.1 Km1,3BPG 0.02 0.022
Km ATP 0.99b 1.1 KmNAD+ 0.08 0.09
Ki G6P 0.02c 0.02c KmNADH 0.004 0.01
HPI Vmf 4.9±1.9 (3) 1.2±0.2 (3) Km Pi 11±1 (3) 29
Vmr 3.4±1.1 (6) 2.8 (2) PGK Vmf 27b 13b
Km G6P 0.9±0.2 (4) 0.4±0.03 (3) Vmr 4.3 3.8
Km F6P 0.07±0.03 (6) 0.05 (2) Km1,3DPG 0.035 0.079
PFK-1 Vmf 0.273d 0.078d Km3PG 0.12 0.13
Km F6P 4.6d 1.0d KmADP 0.67 0.04
Km ATP 0.048d 0.021d KmATP 0.15 0.27
KiATP 1.75d 20d PGAM Vmf 20b 1.4b
KiCIT 3.9d 6.8d Vmr 1.3 0.53
KaF26BP 1.8×10−4d 8.4×10−4d Km3PG 0.18 (2) 0.19
ALDO Vmf 0.23b 0.2b Km2PG 0.04 0.12
Vmr 0.18 NM ENO Vmf 0.51b 0.36b
KmFBP 0.01 0.009 Vmr 0.74 0.4
KmG3P 0.16 NM Km2PG 0.16 0.038
KmDHAP 0.08 NM KmPEP 0.04 0.06
TPI Vmf 5.6 5 PYK Vmf 6.6b 3b
Vmr 56b 42b KmPEP 0.4 0.014
KmDHAP 1.9 1.6 KmADP 0.3 0.4
KmG3P 0.41 0.51 LDH Vmf 13.4 11.4
Vmr 1.8 NM
KmPyr 0.13 0.3
KmLac 4.7 NM
KmNAD 0.07 NM
Km NADH 0.002 NM
Vm in the forward (Vmf) and reverse (Vmr) reactions in U×(mg cytosolic protein)−1; Km in mM. Values taken from a[24]; b[10]; c[66], d[Moreno-Sánchez R, Marín-Hernández A,
Encalada R and Saavedra E, unpublished results]. eVm in U×(mg total cellular protein). The number of independent batches of cells assayed is shown in parentheses; the absence of
parenthesis indicates one assayed preparation. NM, not measured.
Table 3
Glycolytic ﬂux and intermediary concentrations obtained in vivo (cells) and by in silico
modeling for AS-30D cells.
Metabolite 5 mM glucose 1 mM glucosec
In vivoa Model In vivob Model
Gluin 6.2±1 3.4 NM 0.8
G6P 5.3±2.6 6.5 2±0.5 (4) 3.0
F6P 1.5 ±0.7 0.03 0.7±0.2 (4) 0.016
FBP 25±7.6 5.2 0.6±0.3 (3) 0.36
DHAP 10±2.3 14 1±0.3 (3) 4.0
G3P 0.9±0.4 0.3 0.38 (2) 0.09
1,3BPG ND 0.01 NM 0.002
3PG ND 0.01 NM 0.005
2PG ND 0.04 NM 0.016
PEP 0.1±0.02 0.003 NM 0.001
Pyr 2.1±1 0.84 0.72 (2) 0.78
lactate 27±11 Fixed NM Fixed
F2,6BP (×10−3) 6±1(3)b Fixed NM Fixed
citrate 1.7±0.7 Fixed NM Fixed
ATP 5.6±1.2 7.9 6 (2) 4.9
ADP 2.4±0.7 2.1 1.5 (2) 2.9
AMP 3.3±1.4 1.3 NM 3.9
Pi 4.8±1.9 (3)b Fixedd 5 (1)b Fixedd
NADH NM 0.005 NM 0.005
NAD+ 1.3±0.5 (4)b 1.34 NM 1.34
Glycolytic ﬂux 21±9 29 10.5 (2) 14
Metabolite concentrations in mM; ﬂux in nmol lactate min−1 (mg cellular protein)−1.
Values taken from a[10]. bThis study. cIn the model, when this condition was simulated,
Gluout concentration and glycogen synthesis ﬂux were ﬁxed at values of 1 mM and
1 nmol min−1 (mg of cellular protein)−1, respectively. d53% of the total Pi
concentration shown was assumed to be free Pi [22] which was used for pathway
modeling. Figures in parentheses indicate number of independent cellular extracts
assayed. NM, not measured; ND, not detected. Fixed values in the model were at those
experimentally determined in cells.
Table 2
Properties of some glycolytic branches in tumor cells.
AS-30D HeLa
Glycogen metabolism
PGM activity1 0.32±0.1 (3) 0.75±0.2 (3)
Km G1P
3 NM 0.07
glycogen content2 33±30 (5) 171±55 (4)
(26 mM)c (135 mM)c
G1P content3 0.08±0.04 (3) NM
glycogen synthesis ﬂux4 2.2±0.3 (3) 2.4 (2)
glycogen degradation ﬂux4 1.2 (2) 12±2 (3)
Pentose phosphate pathway
G6PDH activity1 0.05a 0.22a
6PG content3 0.35±0.13 (5) 0.39
PPP ﬂux4 0.096±0.03 (3) NM
TA activity1 0.043±0.006 (3) 0.033 (2)
TK activity1 0.010±0.001 (3) 0.037
Ery4P content3 1±0.3 (3) 0.016b
Xyl5P content NM 0.016b
Triglyceride synthesis
αGPDH activity1 NDa NDa
Amino acid metabolism
3PGDH activity1 ND ND
AlaTA activity1 0.046±0.022 (3) 0.012 (2)
Alanine content3 ND ND
Mitochondrial pyruvate metabolism
Flux of pyruvate consumed by mitochondria4 1.8 (2) NM
1U (mg cytosolic protein)−1; 2nmol glucose equivalents (mg total cellular protein)−1;
3in mM; 4nmol min−1 (mg total cellular protein)−1. Values were taken from a[10] and
b[39]. cThe glycogen concentration was calculated by assuming that 1.8 mg total
cellular protein has a volume of 2.28 μl [38]. The values are mean±SD and the number
of independent batches of cells assayed is shown in parentheses: the absence of
parenthesis indicates one preparation assayed. NM, not measured; ND, not detected.
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Table 4
Glycolytic ﬂux and intermediary concentrations obtained in vivo (cells) and by in silico
modeling for HeLa cells.
Metabolite Normoxia Hypoxiac
In vivoa Model In vivob Model
Gluin NM 0.61 NM 1.4
G6P 1.3±0.4 (5)b 0.66 1.4±0.4 (5) 1.0
F6P 0.5±0.2 (5)b 0.01 0.5±0.2 (5) 0.02
FBP 0.38(2)b 0.14 0.23 (2) 0.52
DHAP 0.93±0.07 2.0 0.54 3.6
G3P ND 0.08 NM 0.14
1,3BPG ND 0.0009 NM 0.001
3PG ND 0.006 NM 0.009
2PG ND 0.003 NM 0.004
PEP 0.32 0.0002 NM 0.0003
Pyr 8.5±3.6 2.5 4.2 (2) 2.6
lactate 33 Fixed NM Fixed
F2,6BP (×10−3) 4.2±0.8 (3)b Fixed NM Fixed
citrate NM Fixed NM Fixed
ATP 8.7±3 (5)b 8.4 7.9±4 (5) 7.7
ADP 2.7±1.3 2.2 1.8 (2) 2.1
AMP 0.4 (2)b 1.3 NM 1.2
Pi 7.5 (2)b Fixed 7.8 (2)b Fixed
NADH NM 0.005 NM 0.005
NAD+ NM 1.34 NM 1.34
Glycolytic ﬂux 16±12 (5)b 20 21±9 (5)b 29
Metabolite concentrations in mM; ﬂux in nmol lactate min−1 (mg cellular protein)−1.
Values taken from a[10]. bPresent study. cFor this condition, HK and HPI activities were
determined in cells exposed to hypoxia by 24 h; GLUT activity was estimated from the
protein content obtained by Western-blot analysis (Fig. 2); the ATPase rate was also
adjusted to a value of 4.5×10−3. Figures in parentheses indicate number of
independent cellular batches assayed. NM, not measured; ND, not detected. The ﬁxed
values used for modeling were those experimentally determined in cells, except for Pi
which was adjusted to the free concentration.
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direction.
The kinetics for TPI, PGAM and ENO were depicted by mono-
substrate simple reversible Michaelis–Menten equation:
v =
Vmf
S½ 
Ks
−Vmr P½ 
Kp
1 +
S½ 
Ks
+
P½ 
Kp
in which [S] and [P] are the respective concentrations of substrates
and products with their respective afﬁnity constants.
PFK-1 is an allosteric enzyme showing cooperative behavior with
respect to F6P and hyperbolic kinetics with respect to ATP. The rate
equation for this tetrameric enzyme was the concerted transition
model of Monod, Wyman and Changeux for exclusive ligand binding
(F6P, activators, and inhibitors) [25] together with mixed-type
activation (F2,6BP or AMP or Pi) and simple Michaelis–Menten
terms for ATP and reverse reaction. ATP (at high concentrations) and
citrate are the allosteric inhibitors. L is the allosteric transition
constant; KaF26BP is the activation constant for F26BP; KiCIT and KiATP
are the inhibition constants for citrate and ATP;α and β are the factors
by which KF6P and Vm change when an activator is bound to the active
enzyme form (R conformation in the Monod model).
v = Vmð ATP½ KATP1 + ATP½ KATP0BB@ 1CCA 1 + βF26BPαKaF26BP1 + F26BPαKaF26BP0BB@ 1CCA F6P 1 +
F26BP
αKaF26BP
 
KF6P 1 +
F26BP
KaF26BP
  1 +
F6P 1 +
F26BP
αKaF26BP
 
KF6P 1 +
F26BP
KaF26BP
 
2
664
3
775
3
L 1 +
CIT½ 
KiCIT
 4
1 +
ATP½ 
KiATP
 4
1 +
F26BP
KaF26BP
 4 + 1 +
F6P 1 +
F26BP
αKaF26BP
 
KF6P 1 +
F26BP
KaF26BP
 
2
664
3
775
4
0
BBBBBBBBBBBB@
1
CCCCCCCCCCCCA
−
ADP½  FBP½ 
KADPKFBPKeq
ADP½ 
KADP
+
FBP½ 
KFBP
+
ADP½  FBP½ 
KADPKFBP
+ 1
0
BB@
1
CCAÞ:The ALDO rate equation was the reversible Uni–Bi Michaelis–
Menten equation.
v =
Vmf
FBP½ 
KFBP
−Vmr DHAP½  G3P½ 
KDHAPKG3P
1 +
FBP½ 
KFBP
+
DHAP½ 
KDHAP
+
G3P½ 
KG3P
+
DHAP½  G3P½ 
KDHAPKG3P
The GAPDH kinetics was described by a simpliﬁed ordered Ter–Bi
reversible Michaelis–Menten equation:
v =
Vmf
NAD½  G3P½  Pi½ 
KNADKG3PKPi
−Vmr BPG½  NADH½ 
KBPGKNADH
1 +
NAD½ 
KNAD
+
NAD½  G3P½ 
KNADKG3P
+
NAD½  G3P½  Pi½ 
KNADKG3PKPi
+
BPG½  NADH½ 
KDPGKNADH
+
NADH½ 
KNADH
:
Rate equations for PGK and LDH were represented by the random
Bi–Bi reversible Michaelis–Menten equation for non-interacting
substrates (α and β=1).
v =
Vmf
A½  B½ 
αKaKb
−Vmr P½  Q½ 
βKpKq
1 +
A½ 
Ka
+
B½ 
Kb
+
A½  B½ 
αKaKb
+
P½  Q½ 
βKpKq
+
P½ 
Kp
+
Q½ 
Kq
:
PYK kinetics was represented by the concerted transition model of
Monod, Wyman and Changeux rate equation for exclusive ligand
binding including PEP as well as FBP activation and ATP inhibition,
with simple Michaelis–Menten terms for ADP and reverse reaction.
v = Vm
ADP½ 
KADP
1 +
ADP½ 
KADP
0
BB@
1
CCA
PEP
KPEP
1 +
PEP
KPEP
 3
L 1 +
ATP½ 
KiATP
 4
1 +
FBP
KaFBP
 4 + 1 + PEPKPEP
 4
0
BBBBBBBBBBBB@
1
CCCCCCCCCCCCA
−
ATP½  PYR½ 
KATPKPYRKeq
ATP½ 
KATP
+
PYR½ 
KPYR
+
ATP½  PYR½ 
KATPKPYR
+ 1
0
BB@
1
CCA
0
BBBBBBBBBBBB@
1
CCCCCCCCCCCCA
:
The ATPases rate deﬁned as the ATP-consuming cellular processes
was depicted as mass-action irreversible reaction, in which k was the
rate constant and Si was the substrate concentration.
v = k∏
i
Si:
The DHases and AK were included as reversible mass-action
reactions, in which k1 and k2 are the rate constants, Si is the
concentration of substrate and Pj is the concentration of product.
v = k1∏
i
Si−k2∏
j
Pj
The rest of glycolytic branches were adjusted to irreversible
constant ﬂux.
3. Results and discussion
3.1. Glycolytic enzyme activities, intermediary concentrations and ﬂuxes
in tumor cells
A recurrent difﬁculty encountered in building kinetic models of
metabolic pathways is the lack of all the required kinetic data of the
pathway under study, evaluated in the same cellular model, and
determined under the same experimental conditions. Despite these
inconveniences, some models have been reported for glycolysis in
erythrocytes [26,27], yeast [28] and the human-infecting parasites
Trypanosoma brucei [29] and Entamoeba histolytica [16].
Although there is sufﬁcient kinetic information on glycolytic
enzymes from a wide variety of tumor cells, most studies are not
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reporting metabolite concentrations and metabolic ﬂuxes. This is
particularly evident in studies based only on determinations of
transcriptional changes, from which hypotheses and explanations are
formulated about changes in metabolic ﬂuxes and cellular function
[reviewedanddiscussed in 9].Hence, inorder tohave a complete kinetic
characterization of the glycolytic pathway and its branches in the tumor
cells studied here, the maximal velocities in the forward (Vmf) and
reverse (Vmr) reactions and Km values for substrates (Kms), products
(Kmp) and effectors for each glycolytic enzyme were determined in
cytosolic extracts from AS-30D and HeLa cells at 37 °C and pH 7.0
(Table 1). A pH value of 7.0 was chosen because the intracellular pH
varies from 7.2 to 6.8 when cells are actively consuming glucose [30].
Due to thermodynamic constraints, HK, PFK-1 and PYK activities were
only determined for the forward reaction.
In general, most of the enzyme activity (i.e., Vm) values (Table 1)
were in agreement with those previously reported for the same tumor
cell lines [31,32]. In tumor cells, approximately 50–70% of HK activity is
bound to mitochondria [10,33,34]; thus, to have an accurate determi-
nation of the total HK activity, detergent-permeabilized cells were used
(Table S3). Remarkably, HK, PFK-1 and PGAM activities found in
cytosolic extracts were 7.6, 3.5 and 14 times higher in AS-30D than in
HeLa cells; which contrasted with the similar values obtained for the
rest of the pathway enzymes in both cells (Table 1). HK and PFK-1 are
153 and 27 times lower in rat normal hepatocytes (3 and 10 mU/mg
protein, respectively) than in the AS-30D hepatocarcinoma [10]. On the
other hand,HKactivity in humanmuscle cells is 10 times lowerwhereas
PFK-1 activity in human brain is 3 times higher than inHeLa cells (6 and
258 mU/mgprotein, respectively) [35,36]; however, for amore rigorous
comparison with HeLa cells, normal proliferating cervix epithelial cells
from which these tumor cells derived, should be used.
The Km values were similar in the two cell types (Table 1) and
were within the same interval found in the BRENDA database (http://
www.brenda-enzymes.info/) determined for normal and tumor cells.
The previously reported value for the glycolytic ﬂux in AS-30D cells
under normoxia and 5 mM glucose was 21 nmol min−1 (mg cellular
protein)−1 [10] which was used as reference in the present
study (Table 3). On the other hand, in HeLa cells a value of 16±
12 nmol min−1 (mg cellular protein)−1 (n=5) under normoxic con-
ditions was obtained in the present study (Table 4), which was lower
than the previously reported value of 32±10 nmol min−1 (mg cellular
protein)−1 [10], indicating variability within the same cell line from
culture passage to culture passage. For comparison, normal rat
hepatocytes and normal Chinese hamster ovary cells (CHO-K1) show
glycolytic ﬂux values of 2.4 and 8 nmol min−1 (mg cell protein)−1,
respectively [10,37]. Thus, the tumor cells used here indeed exhibit
increased glycolysis rates compared to normal cells. Glycolytic
metabolite concentrations were also previously reported for AS-30D
cells incubatedwith 5 mMglucose [10] and used as reference (Table 3),
whereas for HeLa cells under normoxia, values for some metabolites
were re-determined (Table 4), ﬁnding no statistical difference with
those previously reported [10].
The enzyme activities,ﬂuxes and intermediary concentrations of the
main glycolytic branches were also evaluated (Table 2): glycogen
synthesis and degradation, PPP, triglyceride and serine synthesis, and
MPM.
Regarding glycogen, HeLa cells showed 5.2 fold higher content than
AS-30D cells and 2.3 fold increased PGM activity (Table 2). The glucose-
1-phosphate (G1P) intracellular concentration (0.08 mM; Table 2) was
lower than its glycolytic precursor G6P in AS-30D cells (5.3 mM;
Table 3). Under the steady-state conditions used, in which extracellular
glucose concentration is 5 mM (see Experimental procedures section),
the glycogen synthesis and degradation rates were 10–18 times lower
(Table 2) than the glycolytic ﬂuxes (Tables 3 and 4) in both tumor cells;
with the exception of the glycogen degradation ﬂux in HeLa cells which
was 75% the glycolytic ﬂux. The most probable reason for the higheractivity in the glycogen degradation branch in HeLa cells was that these
are cultured in Dulbecco-MEM medium containing 25 mM glucose,
whereas the glucose concentration found in AS-30D ascites ﬂuid is
0.026 mM [38]. Cultivation of HeLa cells under high (25 mM) glucose
induces the expression of the low afﬁnity glucose transporter GLUT1,
whereas AS-30D hepatoma developed intra-peritoneally in rats
predominantly express the high afﬁnity GLUT3 [24]. In consequence,
the incubation of HeLa cells in ﬂuxes assay medium containing lower
glucose (compared to culturemedium)most probably promoted strong
activation of glycogen degradation to compensate for the diminished
glucose uptake; this compensatory mechanism was apparently not
required in AS-30D hepatoma.
In the oxidative section of PPP (Table 2), higher G6PDH activity
was found in HeLa than in AS-30D cells, but similar 6PG concentra-
tions. On the other hand, the activities of the PPP non-oxidative
section enzymes TA and TK were similar to reported values for the
same and other tumor cells (0.019–0.208 and 0.022–0.108 U
(mg protein)−1, respectively) [17,39]. A lower Ery4P concentration
in comparison to that of glycolytic intermediaries (G6P, FBP, and
DHAP)was determined, whichwas slightly higher than the previously
reported value for Krebs ascites hepatoma cells (0.5 nmol/mg cellular
protein) [40]. The lower PPP ﬂux and enzyme activities (Table 2)
compared to glycolytic ﬂux (see text above for values) and enzyme
activities (Table 1) suggested low nucleotide synthesis and hence
negligible cellular proliferation, as expected from incubationsmade in
a saline buffer for short times (3–10 min). For A549 lung carcinoma
and C6 rat glioma, PPP ﬂuxes of 1 and 6 nmol/min*mg protein,
respectively, were determined by using radio-labelled glucose and
lengthy incubations of 4–6 h in culturemediumwith glucose and fetal
bovine serum, conditions under which cellular growth is favored
[41,42]. Then, it seems possible that the PPP ﬂuxes, determined here
from 6PG changes (Table 2), were underestimated as the variation in
the cellular 6PG content was small and close to the lower detection
limit of the method used. Further evaluation of the PPP ﬂux in AS-30D
and HeLa cells either with radio-labelled glucose or under cell growth
conditions for longer times should resolve this apparent discrepancy.
Low or negligible αGPDH activities, which are involved in
triglyceride synthesis, have been reported for several tumor cells
[43]; accordingly, αGPDH activity was not detected in AS-30D and
HeLa cells [10]. Triglyceride synthesis can also be initiated by DHAP
acylation in a reaction catalyzed by DHAP-acyltransferase [44];
however, this enzyme was not determined in the present study and
this branch was not included in the model.
A previous report indicated that serine metabolism is accelerated
in tumor cells [45]; however, the activity of 3-phosphoglycerate
dehydrogenase was not detected when measured in the 3PG
oxidation direction (Table 2) and thus, this branch was not included
in the model. Alanine transaminase activity (AlaTA) measured in the
pyruvate synthesis direction was low in both AS-30D and HeLa cells
(Table 2). These low activities correlated with undetectable alanine
levels in cellular extracts.
The MPM rate was 11.7 fold lower than the lactate production rate,
suggesting that anaerobic glycolysis was favored. It might be possible
that the mitochondrial pyruvate transporter expressed in AS-30D cells
also has low afﬁnity and low rate as described for Morris 44 and 3924A
hepatomas (Vm=5–12 mU/mg mitochondrial protein and
KmPyr=0.74–1.1 mM) [46]. The expression of a low activity/lowafﬁnity
pyruvate transporterwould favor a higher pyruvateﬂux towards lactate
because of LDH higher activity and afﬁnity (Vm=2.0 U/mg cellular
protein, Table S3; KmPyr=0.13 mM, Table 1). Contributing to the
unusually high endogenous pyruvate pool (Tables 3 and 4) may be the
active oxidation of alternative substrates such as glutamine, glutamate
and proline, which generatemalate and hence pyruvate by the action of
over-expressed malic enzyme in cancer cells [38,47]. In addition, the
onset of the Crabtree effect (OxPhos inhibition by external glucose)
should also promote an elevation in the intracellular pyruvate pool [30].
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The kinetic model of glycolysis in AS-30D cells was constructed by
using theGepasi software. The kinetic parametersVm,Km for substrates,
products and modulators for the pathway enzymes and glucose
transporter from external glucose to lactate production as well as the
enzyme activities and ﬂuxes of the pathway branches experimentally
determined were used to fulﬁll the parameters of the rate-equations
describing each reaction as detailed in the Experimental procedures
section. The metabolite concentrations and the pathway ﬂuxes of
glycolysis determined in vivo under steady-state conditions (Table 3)
and the control distribution obtained by elasticity analysis previously
reported by our research group [10] (Table 5) were used as reference
parameters for model validation.
In consequence, for model building and validation, a reﬁnement
process was recurrently necessary, which in turn prompted an
experimental re-evaluation of the kinetic properties of some enzymes
aswell as thedeterminationof neglectedmetabolite concentrations and
the inclusion of somebranches to improvemodel reproduction of in vivo
pathway behavior. Thus, this dynamic interplay betweenmodeling and
experimentation led to several model and rate equation modiﬁcations,
from which the three most important are described below.
3.2.1. Kinetics of PFK-1
The ﬁrst draft of the model included the reactions from external
glucose to lactate production and the branch of glycogen metabolism
(Fig. 1), in which a simpliﬁed version of the PFK-1 rate-equation
(hyperbolic kinetics) was used. However, G6P level was too high
whereas those of DHAP and G3P were too low. Thus, an improvement
of the PFK-1 reaction was necessary.
There is a lack of detailed kinetic analyses of PFK-1 in normal and
tumor cells, in which a simple Hill equation for only one modulator is
used. Hence, a kinetic characterization of PFK-1 was carried out in AS-
30D andHeLa cells (see Experimental procedures section), resulting in a
rate-equation that followed the concerted transition model of
Monod, Wyman and Changeux together with non-essential activa-
tion by F2,6BP (or any other allosteric activator) (Moreno-Sánchez R.,
Marín-Hernández A., Encalada R. and Saavedra E., unpublished results).
The intracellular concentrations of F2,6BP, AMP, ATP and citrate were
also determined (Tables 3 and 4). As the activating effect of F2,6BP
overcame the inhibitory effect of citrate and ATP, at the tumor phys-
iological concentrations of thesemodulators (see a simulation in Fig. S1
in supplementary material), the PFK-1 rate in the presence of phys-
iological F2,6BPwas2 fold higherwith the concomitant increased in FBP
and DHAP to near-physiological levels. However, a marked decrease in
the Gluin, G6P and F6P concentrations was attained.
3.2.2. Kinetics of HPI
Through modeling it was noted that a decrease in the HPI activity
resulted in a better prediction of the G6P concentration and the
glycolytic ﬂux. Hence, the effect of a wide variety of metabolites (ATP,
AMP, Pi, PPi, citrate, Ery4P, DHAP, G1P, lactate, 6PG, FBP and F2,6BP)
on HPI activity was examined. Most of them showed no effect (Table
S5 in supplementary material); in contrast low Ki values for Ery4P
(0.8–2.5 μM), 6PG (6.8–18 μM) and FBP (60–170 μM) were deter-
mined (Table S6). Thus, multiple competitive-type inhibition by Ery4P
(Fig. S2), 6PG and FBP was incorporated in the HPI rate-equation. The
potent HPI inhibition by these metabolites was not particular of the
tumor enzyme, since it was previously reported for the normal rat
brain, and rabbit liver and muscle HPIs [48–50] and they also
modulated the enzymes from rat hepatocytes, yeast and E. histolytica
(Table S6). Therefore, the intracellular concentrations of 6PG and
Ery4P were also determined in the tumor cells, and in consequence
the oxidative section of PPP and TK reaction with their corresponding
ﬂuxes (Table 2) and metabolite interactions with HPI were also
included in the model (Fig. 1).3.2.3. Kinetics of the FBP consuming block of enzymes and GAPDH
By including the two modiﬁcations described above, the modeled
FBP concentration was still several times lower than the physiological
concentration, indicating an unrealistic high rate by the consuming
block of this metabolite. Thus, the effects of G6P, F6P, Pi, ATP, AMP,
Ery4P, F2,6BP and PPi on the enzymes of the ALDO–ENO segment
were tested (see Table S5).
ALDO activity was not modulated by any of these metabolites.
Although GAPDH was inhibited by ATP (with non-competitive
inhibition, Ki=4.3 mM) and ENO was inhibited by DHAP and ATP
(non-competitive inhibition, Ki=31 mM, and uncompetitive inhibi-
tion, Ki=14 mM, respectively), these Ki values were far from the
physiological concentrations, and their effects were not included in
the rate-equations.
GAPDH from AS-30D cells showed low afﬁnity for Pi (Table 1;
Fig. S3) which suggested that Pi availability might regulate the
enzyme activity. High KmPi values for GAPDH from bovine liver,
human muscle and sarcoma [51,52] have also been documented.
Thus, contrary to other glycolysis kinetic models in which Pi is
considered saturating and hence it is not included as pathway
metabolite, in the present model Pi was included in the GAPDH
rate-equation. On the other hand, from the total intracellular Pi
concentration determined (Table 3) only 53% [22] was assumed to be
free (i.e., 2.5 mM); this free Pi concentration was used for modeling
and was in agreement with values previously determined by nuclear
magnetic resonance in rat liver and heart (1.3–2.8 mM) [53,54].
3.2.4. Properties of the kinetic model of glycolysis in AS-30D hepatoma
cells
By incorporating (i) the PFK-1 complex rate equation, (ii) the
inhibition of FBP, 6PG and Ery4P on HPI, and (iii) Pi in the GAPDH rate-
equation, the kinetic model was able to predict with high accuracy the
concentration of most of the pathway metabolites and ﬂux rate
determined in living cells (Table 3). The most signiﬁcant exceptions
were the predicted FBP (4.8 times lower) and F6P (50 times lower)
concentrations. It was found that the FBP steady state concentration
directly depended on the Pi concentration within the reported
physiological range (Table S7). On the other hand, only by decreasing
to 20% the PFK-1 activity, the F6P reached the physiological level;
however, this decrease was not experimentally supported because of
the strong activation by F2,6BP, AMP and/or Pi. Moreover, under this
last condition of 20% activity, PFK-1 became themain ﬂux control step,
which was in disagreement with the results obtained by elasticity
analysis [10]. Hence, still another unknown kinetic mechanism seems
to also modulate the in vivo PFK-1 rate.
3.2.5. Control distribution of glycolysis in AS-30D
The analysis performed by Gepasi provided the CJEi of all the
pathway steps (Table 5). Modeling indicated that the ﬁrst three
reactions of glycolysis exerted most of the ﬂux-control with
HK≥HPINGLUT (ΣCJEi=1.04; Table 5). This control distribution was
in agreement with the C JEi obtained by elasticity analysis, which
indicated that the G6P producer block (GLUT and HK) exerted the
main ﬂux-control (ΣC JEi=0.65–0.71) [10], whereas the C
J
HPI value was
not possible to be discerned in the previous study, because the high
experimental dispersion masked ﬂux-control differences among the
different blocks of enzymes analyzed.
HK and HPI showed high ﬂux-control because they were strongly
inhibited by glycolytic and PPP intermediaries. It was previously
demonstrated [10] that HK exerted signiﬁcant control on ﬂux in
cancer cells because it was strongly inhibited by its product G6P,
despite its higher levels of expression compared to normal cells. In
particular, AS-30D cells over-expressed the HK-II isoform [24] which
partitioned between the cytosol and mitochondria, the latter showing
the same afﬁnity constants for glucose, ATP and G6P than the former,
cytosolic HK II [10]. Thus, although a hallmark of tumor cells is the
Table 5
Flux control coefﬁcients obtained in vivo (cells) and by kinetic modeling.
Enzyme C
J
Ei
AS-
30D
AS-30D model HeLa model
In vivoa 5 mM
Glucose
1 mM
Glucose
Normoxia Hypoxia
GLUT+
HK
0.2 0.12 0.39 0.32
0.71a 0.44 0.50 0.08 0.2
HPI+
PPP+
glycogen synthesis
−0.02a 0.4 0.46 0.05 0.1
−0.004 −0.009 −0.009 −0.005
−0.1 −0.1 −0.1 −0.06
Glycogen degradation NM 0.05 0.11 0.57 0.33
PFK-1 0.06a 0.02 0.03 0.03 0.12
ALDO+TPI+GAPDH+
PGK+PGAM+ENO+
PYK+LDH
0.24a 0.08
(GAPDH 0.05)
0.009 0.01 0.06
MPM NM 0.003 0.02 −0.004 −0.001
TK NM 0.01 0.023 0.014 0.01
ATPases NM −0.1 −0.16 −0.02 −0.05
a Values taken from [10]. PPP, pentose phosphate pathway; MPM, mitochondrial
pyruvate metabolism. NM, not measured. For AS-30D, both conditions were modeled
under normoxia. For HeLa, both conditions were modeled in the presence of 5 mM
glucose.
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regulatory mechanisms are apparently preserved to avoiding unre-
stricted increase in ﬂux, which in turn can lead to cell death because of
the turbo design of glycolysis [55]. On the other hand, HK also exerts
signiﬁcant ﬂux control in normal cells [26,56] making this step less
suitable for speciﬁc drug targeting in cancer cells.
In turn, HPI displayed a high C
J
E, despite being one of the most
active enzymes in the pathway when determined under Vm
conditions in the absence of modulators (Table 1). However, the
potent combined HPI inhibition by FBP and the PPP intermediaries
6PG and Ery4P led to severe activity decrease, becoming now limiting
for pathway ﬂux. The modulation of HPI activity by these metabolites
might be a control mechanism of the G6P concentration which in turn
may exert control on (a) the synthesis of glycogen; (b) the PPP ﬂux for
NADPH and ribose-5P syntheses; (c) the production of UDP-
glucuronate for proteo-glycan and glycoproteins synthesis and
xenobiotic detoxiﬁcation; and (d) the cellular ATP homeostasis by
avoiding its depletion through an enhanced HK reaction. Remarkably,
this HPI inhibition was also present in the yeast and ameba enzymes.
As the potent inhibition on HPI here described was not considered in
previous published models of glycolysis, which might change the
control distribution, the putative HPI controlling role remains to be
experimentally evaluated in other biological systems. On the other
hand, the signiﬁcant HPI ﬂux control in AS-30D cancer cells (cf.
Table 5), and its negligible controlling role in normal cells [26,56],
indicates that this step is a suitable therapeutic target.
The results onHPI andGAPDHkinetics emphasize the importance, for
metabolic modeling, of an extensive knowledge of the enzyme kinetic
properties, which should not be restricted to the sole characterization
with their substrates, but also to its interactionwith its products andwith
other pathway intermediaries, which are not always assayed when
studying the puriﬁed enzymes. This has been previously demonstrated
by reconstitution of pathway segments of amebal glycolysis [57], in
which interactions with non-substrate metabolites but pathway gly-
colytic intermediaries were elucidated for several enzymes.
GLUT displayed signiﬁcant ﬂux control (CJGLUT=0.2; Table 5) as
previously suggested by elasticity analysis [10] and its kinetic
properties [24]. From the main four isoforms (GLUT1–4), AS-30D
cells mainly express GLUT3 which has a high afﬁnity for glucose
(Km=0.52 mM) [24]. Moreover, by over-expressing all GLUT iso-
forms in Xenopus oocytes and determining the kinetics parameters
with 2-deoxyglucose, it was previously concluded that GLUT3 is the
transporter with the highest catalytic efﬁciency [reviewed in 5]. In AS-30D cells, GLUT displayed lower activity and catalytic efﬁciency (Vm/
Km) than HK and HPI; however, the inhibitory effect on the latter two
by glycolytic and PPP metabolites decreased their activities to levels
that conferred ﬂux-controlling roles. In contrast, in the kinetic models
of glycolysis in yeast [28], T. brucei [29], E. histolytica [16] and heart
[56], GLUT contributed by N50% to ﬂux-control. This difference in
GLUT ﬂux control between tumor cells and heart indicates that this
step might not be an adequate target for cancer treatment, because its
inhibition would preferentially affect normal cells over tumor cells.
The rest of the ﬂux-control (0.08) was found in the ALDO–LDH
segment (Table 5), whichwas also in agreementwith that obtained by
elasticity analysis (Σ C JEi=0.24) [10]. Within this segment, most of the
control was accounted by GAPDH (C JGAPDH=0.05), due to its Pi low
afﬁnity and hence its dependence on the variation of the Pi
concentration in AS-30D cells (Table S7). The ATP demand (ATPases)
showed a low ﬂux control but of the negative sign, indicating that this
reaction competes with the glycolytic ATP-consuming steps for ATP
thus inhibiting the glycolytic ﬂux.
3.2.6. Why a step controls ﬂux?
The HK elasticity coefﬁcient (Table S8) and the catalytic efﬁciency
for ATP (Vm/Km) were among the lowest in both AS-30D and HeLa
glycolysis, indicating near-saturation with concomitant activity
insensitivity to variations in ATP, relatively lower transformation
efﬁciency and hence ﬂux limitation at this level. In turn, the reasons
for the HPI high ﬂux control coefﬁcient resided in its step-wise
increasing elasticities (sensitivities) towards the potent inhibitors
FBP, 6PG and Ery4P, and low elasticity for its product F6P, indicating
saturation, and hence strong inhibition and prevalence of the reverse
over the forward reaction. Similarly, GLUT catalytic efﬁciency was the
lowest among the pathway steps, indicating strong ﬂux restriction; in
addition, in HeLa cells, GLUT elasticity for its product, Gluin, was one of
the lowest, indicating near-saturation and perhaps product-inhibition
and signiﬁcant reaction reversibility and correlating with a higher
GLUT ﬂux control in these cells. On the other hand, the low ﬂux-
control exerted by PFK-1 is explained by the low elasticity towards
activators, indicating saturation and hence full activation. If PFK-1
were not fully activated, it would very likely the main controlling step
as its elasticity towards F6P is the lowest. On the other hand, the PFK-1
elasticities for citrate, and for their products FBP and ADP, were
extremely low because these metabolites were not sensed due to the
high Ki and Km, and low intracellular levels.
3.2.7. Control of metabolite concentrations
The control of the concentration of G6P, PEP and ATP depended on
GLUT, HK, HPI and ATPase activities in AS-30D glycolysis and on GLUT,
glycogen degradation and ATPase in HeLa glycolysis (Table S9). For
the F6P concentration, PFK-1 in both AS-30D and HeLa glycolysis was
the predominant controlling step, as expected.
3.2.8. Model robustness
The modeled pathway behavior (i.e., ﬂux-control and concentra-
tion control distribution, ﬂux rates and metabolite concentrations)
was not signiﬁcantly altered by changing (decreasing by half or
increasing by 2 times) the kinetic parameters of most steps and PPP
ﬂux (data not shown). Exceptions were (i) control distribution and/or
metabolite concentrations, which varied by more than 50% when
changing the main controlling steps GLUT, HK, HPI, PFK-1 and GAPDH
Vm values (AS-30D model) or GLUT, glycogen degradation, PFK-1 and
GAPDH Vm values (HeLa model, see below); (ii) FBP concentration,
which varied by 21–100% when changing ALDO Vm and Km values in
both models; and (iii) DHAP concentration, which varied by 9–100%
when changing TPI, GAPDH, PGK, PGAM, ENO and PYK Km values (AS-
30D) or only TPI Km values (HeLa). Both models were also highly
sensitive to changes in the ATPase kinetics, revealing that this step is
the weakest component in conferring stability to the pathway.
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behavior showed satisfactory robustness, further validating the
models constructed for both cancer cell lines.
3.3. Kinetic model of glycolysis in HeLa tumor cells
The kinetic model for HeLa cells glycolysis was constructed based
also on the experimental parameters determined in these cells
regarding enzyme activities (Table 1), metabolite concentrations
and ﬂuxes of the glycolytic pathway (Table 4) and its branches
(Table 2), and the rate equations used in the AS-30D model.
Themajority of themetabolite concentrations and ﬂuxes predicted
by the model correlated well with the in vivo concentrations except
for F6P and PEP, which were 50- and 1600-times lower, respectively
(Table 4). These discrepancies indicated that some kinetic experi-
mentation-based reﬁnement was still needed, most probably at the
level of PFK-1 and ALDO, and PYK.
According to the model, the main ﬂux controlling steps in HeLa
cells, grown under normoxic and high glucose (25 mM) conditions,
and assayed in the presence of physiological glucose (5 mM), were
the glycogen degradation pathway and GLUT (C Jglycogen degradation+
C JGLUT=0.96), whereas the control exerted by the block of HK+HPI+
PFK-1 was 0.16 (Table 5). The higher control attained by GLUT in HeLa
cells compared to AS-30D was caused by the over-expression of the
GLUT1 isoform, which displays low rate in these cells (0.017 nmol/
min*mg cellular protein) and low afﬁnity for glucose (9mM), resulting
in a lower catalytic efﬁciency than that of GLUT3 in AS-30D cells [24]. At
physiological glucose concentration (5mM), the rate equation for GLUT1
predicts an activity of 25% of its maximal activity (4 nmol min−1 mg
cellular protein−1), which cannot completely account for the observed
glycolytic ﬂux (16±12 nmol lactate min−1 mg cellular protein−1). In
consequence, the glycogen degradation pathway activates to provide the
bulk of glucose equivalents to reach the observed high glycolytic ﬂux.
The high ﬂux through the glycogen degradation pathway and the
higher PGMactivity determined inHeLa cells, compared toAS-30D cells,
supported a relevant role for this pathway in delivering glucose
equivalents for glycolytic ﬂux (Table 2). In fact, HeLa cells incubated in
the absence of glucosewere able to produce lactate (7 nmol·min−1·mg
cellular protein−1), which corresponded to 22% of the lactate produced
in its presence. In contrast, lactate production in AS-30D cells was
completely dependent on available external glucose [10]. On the other
hand, at 25 mM glucose, the predicted GLUT1 rate in HeLa cells
(11.7 nmol min−1 mg cellular protein−1) can easily cope with the
requiredglucose supply for theglycolytic pathway,whichbrings about a
decreased ﬂux control exerted by both glycogen degradation and GLUT
(data not shown). Moreover, it is well documented that glycogen
phosphorylase is inhibited by high glucose and G6P levels, with the
consequent decrease in glycogenolytic ﬂux [58]. It might be possible
thatwhen HeLa cells are incubatedwith 5 mMglucose, the intracellular
concentrations of these metabolites concomitantly also diminish as a
consequence of the low GLUT activity, thus favoring glycogen
phosphorylase activation, increasing glycogenolysis and hence acquir-
ing higher ﬂux-control.
Thus, the different control distribution between AS-30D and HeLa
cells was probably related to the environmental prevailing conditions
in which cells were grown. The low glucose concentration encoun-
tered by AS-30D cells in the rat intraperitoneal cavity (0.026 mM)
favored the expression of a high afﬁnity GLUT and led to a relatively
low glycogen content, whereas the HeLa cell high-glucose containing
culture medium (25 mM) favored the expression of a low afﬁnity
GLUT and led to high glycogen content.
3.4. Kinetic modeling under different steady-states
It is worth emphasizing that the control distribution as obtained by
modeling can only be applied to the speciﬁc steady-state conditionanalyzed, which depended on a particular set of enzyme activities
expressed in the cells. Therefore, it was interesting to test the validity
of the model predictions in cells subjected to other environmental
conditions.
During tumor growth, cells localized far from blood vessels are
exposed to hypoxia and nutrient starvation. It is well known that
under hypoxia the transcription factor HIF-1α induces an increase in
the transcription of most glycolytic genes resulting in an over-
expression of the enzymes and transporters of this pathway
[reviewed in 5]. On the other hand, under low glucose concentration,
an increase transcription of HK-II, PFKB3, GLUT1 and GLUT3 induced
by AMP kinase has been observed [59,60].
With the validated kinetic models, low availability of external
glucose (for AS-30D) and hypoxia (for HeLa) conditions were
examined. To this end, it seemed that only a small set of data was
needed to be experimentally re-evaluated by focusing on the steps
with the highest control. Although a generalized increased activity
under hypoxia in the glycolytic enzymes has been documented for
most tumor cells [reviewed in 1], a higher increase activity in non-
controlling steps does not affect pathway ﬂux rate and ﬂux-control
distribution (Section 3.2.8 above).
3.4.1. Modeling AS-30D glycolysis under low glucose concentration
Steady-state intermediary concentrations and glycolytic ﬂux
determined in AS-30D cells incubated with 1 mM glucose were
~50% lower for G6P, F6P, G3P and Pyr, and ﬂux rate, and one order of
magnitude lower for FBP and DHAP (Table 3). The AS-30D kinetic
model predicted well the values for ﬂux and G6P, FBP, G3P and Pyr
concentrations found in the cells, but for DHAP and G3P the values
were 4 times higher and 4.2 times lower, respectively (Table 3).
Essentially the same ﬂux-control distribution was attained under low
glucose (HK≥HPINGLUT), with the glycogen degradation branch
gained more control, as expected (Table 5).
3.4.2. Modeling HeLa glycolysis under hypoxic conditions
HeLa cells exposed to hypoxia did not show signiﬁcant changes in
G6P, F6P and ATP steady-state concentrations, whereas a 31%
increased glycolytic ﬂux was indeed found compared to cells grown
under normoxia (Table 4). Increased enzyme activities under hypoxia
for HK and HPI were also determined (37% and 30%, respectively)
whereas a 252% increased protein content for GLUT was determined
byWestern-blot analysis (Fig. 2) and then a corresponding increase in
transport activity was assumed for modeling. By introducing these
new parameters, the kinetic model satisfactorily predicted the ﬂux
rate and the metabolite concentrations (Table 4). In addition, hypoxia
did not bring about a change in the control distribution (glycogen
degradationNGLUTNHK), although the difference in the control
exerted by glycogen degradation and GLUT compared to normoxia
(31%) was mainly transferred to HK, PFK-1 and the ﬁnal pathway
segment (Table 5).
The experiment of subjecting HeLa cells to hypoxia and nutrient
starvation and determining ﬂuxes, activities and metabolite concentra-
tions is difﬁcult to achieve because of low cell number yields. Therefore,
the HeLa model was used to predict the pathway behavior under both
conditions (hypoxia and 1 mM glucose; data not shown). The results
showed a similar control distribution to that obtained under normoxia
and 5 mMglucose (column5 of Table 5) althoughwith decreases inﬂux
and metabolite concentrations by 36–86%, compared to hypoxia alone
(column 6 of Table 5). These accurate predictions under a variety of
physiological steady-state conditions revealed again high robustness of
the kinetic models adding further validation.
3.5. Enzyme titration for the identiﬁcation of the best drug targets
The kinetic models allow the relationship between glycolytic ﬂux
and a given enzyme activity to be analyzed (Fig. 3). As long as the
Fig. 2. Glucose transporter protein content after hypoxia treatment in HeLa cells.Bar data represent the mean±SD of at least three different preparations. N, normoxia; H, hypoxia.
Western-blot analysis was carried out according to reference [19].
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tool for identifying the drug targets with the highest therapeutic
potential in a metabolic pathway. Thus, GLUT, HK, HPI, PFK-1, TPI and
PYK activities were varied in the AS-30D hepatoma glycolysis model,
or GLUT, HK, HPI, TPI and the glycogen degradation branch in the HeLa
model, to establish how much these potential drug targets should be
inhibited for attaining signiﬁcant decrement in the glycolytic ﬂux and
ATP concentration. To decrease the pathway ﬂux (or the ATP
concentration; data not shown) by 50%, it was required to inhibit,
individually, the main controlling steps HK, HPI or GLUT by 76–78% in
AS-30D glycolysis (Fig. 3A), whereas those of HeLa glycolysis GLUT,
HK, HPI or glycogen degradation required 87–99% inhibition (Fig. 3B).
In contrast, to achieve a similar ﬂux diminution, the non-controlling
steps PFK-1, PYK or TPI in AS-30D glycolysis needed to be inhibited by
71%, 99.2% and 99.5%, respectively (Fig. 3A). Interestingly, 50%0 20 40 60 80 100
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Fig. 3. Dependence of tumor glycolyticﬂuxon enzyme activity. The reference 100% enzyme
activity values were those corresponding to the respective Vm values for the forward
reaction (Tables 1 and S3) whereas 100% ﬂuxes were those predicted by eachmodel (A for
AS-30D; B for HeLa cells), whichwere the ﬂuxes through LDH (29 and 20 nmol min−1 (mg
cell protein)−1, respectively; Tables 3 and 4). In A, enzymes, transporters and braches were
(a)GLUT+HK+HPI;(b)GLUT+HK; (c)HKorHPI; (d)GLUT; (e)PFK-1; (f) PYKand(g)TPI.
In B, (a) GLUT+glycogen degradation; (b) glycogen degradation; (c) GLUT; (d) HK; (e) HPI
and (f) TPI.When twoormore stepswere titrated, identical variation in activitywas applied.
A decrease of the Vmf value was accompanied by a proportional decrease in the Vmr value.inhibition of ﬂux (or ATP concentration) was attained, in AS-30D
glycolysis, when GLUT+HK or GLUT+HK+HPI were decreased
simultaneously by the same magnitude, 63% and 47% inhibition,
respectively, whereas in HeLa glycolysis, when GLUT+glycogen
degradation were decreased simultaneously by 48% (Fig. 3B).
4. Concluding remarks
The kinetic models for both tumor cells predicted reasonably well
ﬂuxes and metabolite concentrations found in living cells. To achieve
high robustness, the models were built up with the kinetic properties
of each individual enzyme determined experimentally including
(a) the most common ligands (substrates, products and modulators),
and (b) the interactions of several other pathway intermediaries with
the enzymes (Fig. 1). Also, the great majority of the changes made to
improve and reﬁne the models were based on “wet” experimentation.
This allowed us to identify some mechanisms by which a traditionally
considered non-controlling enzyme such as HPI may exert signiﬁcant
control on tumor glycolysis. However, further rounds of model
reﬁnement are still necessary to reach more prediction accuracy,
especially for F6P and PEP concentrations. Nevertheless, the present
models may serve to predict the pathway behavior under other
physiological conditions and in other cancer cell lines as long as the
most controlling steps are experimentally evaluated.
Thus, kinetic modeling is a helpful theoretical–experimental
approach to identifying the most promising therapeutic targets. It
has been proposed that inhibition of glycolysis in tumor cells can be
an alternative therapeutic strategy [6,61] and several therapeutic
targets have been proposed (GLUT1, HKII, PFKFB3, GAPDH, LDH, and
MCT) [37, reviewed in 62–65]. It then results of clinical relevance to
experimentally evaluate whether such targets are indeed ﬂux control
steps of the tumor cells' pathway.Moreover, it would be desirable that
such targets have high ﬂux control in tumor cells, but low control in
host, normal cells.
In normal cells, HK and PFK-1, together with GLUT, exert the main
control on the glycolytic ﬂux [reviewed in 8]. However, due to the
different enzyme activity levels, different control distribution was
expected, and demonstrated here, between HeLa (glycogen degrada-
tion≥GLUTNHK) and AS-30D (HK≥HPINGLUT) cells; and between
these and normal cells: PFK-1 played a minor role on ﬂux- and
metabolite-control in cancer cells, except for the hypoxia condition.
The main ﬂux-controlling steps are the targets with the higher
potential to diminish the glycolytic ﬂux in the two cancer cells
examined. Although the glycogen degradation pathway was a high
controlling step in HeLa glycolysis, it could not be an appropriate drug
target because glycogen degradation cannot be sustained by pro-
longed periods of time.
In summary, drug-design studies targeting the most controlling
enzymes or transporters in tumor glycolysis might have more
promissory results than targeting non-controlling enzymes which
usually require more potent and speciﬁc inhibitors to accomplish the
required full inhibition to achieving effect on function. Another
766 A. Marín-Hernández et al. / Biochimica et Biophysica Acta 1807 (2011) 755–767strategy would be that of a multi-targeted therapy against the most
controlling steps as previously suggested [cf. Fig. 3; see also 9].
From a therapeutic point of view, the kinetic models are useful for
predicting how pathway ﬂuxes and ATP concentrationmay varywhen
one or more steps are inhibited. The results of the simulations
indicated that only the simultaneous inhibition of the controlling
steps may have signiﬁcant impact on glycolytic ﬂux and ATP
concentration. Other interventions such as inhibition of solely one
controlling step, or worse, of non-controlling steps will bring about
negligible effects on pathway behavior. For the latter, their negligible
ﬂux-control coefﬁcients demand the design of highly potent and very
speciﬁc inhibitors for the tumor steps or their full gene transcription
or translation blockade.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.bbabio.2010.11.006.
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